Literature DB >> 20348403

Quantification of galactose-1-phosphate uridyltransferase enzyme activity by liquid chromatography-tandem mass spectrometry.

Yijun Li1, Adam S Ptolemy, Lauren Harmonay, Mark Kellogg, Gerard T Berry.   

Abstract

BACKGROUND: The diagnosis of galactosemia usually involves the measurement of galactose-1-phosphate uridyltransferase (GALT) activity. Traditional radioactive and fluorescent GALT assays are nonspecific, laborious, and/or lack sufficient analytical sensitivity. We developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay for GALT enzyme activity measurement.
METHOD: Our assay used stable isotope-labeled alpha- galactose-1-phosphate ([(13)C(6)]-Gal-1-P) as an enzyme substrate. Sample cleanup and separation were achieved by reversed-phase ion-pair chromatography, and the enzymatic product, isotope-labeled uridine diphosphate galactose ([(13)C(6)]-UDPGal), was detected by MS/MS at mass transition (571 > 323) and quantified by use of [(13)C(6)]-Glu-1-P (265 > 79) as an internal standard.
RESULTS: The method yielded a mean (SD) GALT enzyme activity of 23.8 (3.8) mumol x (g Hgb)(-1) x h(-1) in erythrocyte extracts from 71 controls. The limit of quantification was 0.04 micromol x (g Hgb)(-1) x h(-1) (0.2% of normal control value). Intraassay imprecision was determined at 4 different levels (100%, 25%, 5%, and 0.2% of the normal control values), and the CVs were calculated to be 2.1%, 2.5%, 4.6%, and 9.7%, respectively (n = 3). Interassay imprecision CVs were 4.5%, 6.7%, 8.2%, and 13.2% (n = 5), respectively. The assay recoveries at the 4 levels were higher than 90%. The apparent K(m) of the 2 substrates, Gal-1-P and UDPGlc, were determined to be 0.38 mmol/L and 0.071 mmol/L, respectively. The assay in erythrocytes of 33 patients with classical galactosemia revealed no detectable activity.
CONCLUSIONS: This LC-MS/MS-based assay for GALT enzyme activity will be useful for the diagnosis and study of biochemically heterogeneous patients with galactosemia, especially those with uncommon genotypes and detectable but low residual activities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348403      PMCID: PMC3676861          DOI: 10.1373/clinchem.2009.140459

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  18 in total

1.  Quantitative Beutler test for newborn mass screening of galactosemia using a fluorometric microplate reader.

Authors:  A Fujimoto; Y Okano; T Miyagi; G Isshiki; T Oura
Journal:  Clin Chem       Date:  2000-06       Impact factor: 8.327

2.  GALACTOSE-1-PHOSPHATE URIDYL TRANSFERASE ACTIVITY IN GALACTOSAEMIA.

Authors:  N G WONGIN; W R BERGREN; G N DONNELL
Journal:  Nature       Date:  1964-08-22       Impact factor: 49.962

3.  Congenital galactosemia, a single enzymatic block in galactose metabolism.

Authors:  K J ISSELBACHER; E P ANDERSON; K KURAHASHI; H M KALCKAR
Journal:  Science       Date:  1956-04-13       Impact factor: 47.728

4.  Improved transferase assay for cultured fibroblasts.

Authors:  J D Russell
Journal:  Biochem Genet       Date:  1968-01       Impact factor: 1.890

5.  Simultaneous determination of multiple intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by liquid chromatography-mass spectrometry.

Authors:  Bing Luo; Karsten Groenke; Ralf Takors; Christian Wandrey; Marco Oldiges
Journal:  J Chromatogr A       Date:  2007-02-16       Impact factor: 4.759

6.  Improved method for measuring galactose-I-phosphate uridyl transferase activity of erythrocytes.

Authors:  E Beutler; M C Baluda
Journal:  Clin Chim Acta       Date:  1966-03       Impact factor: 3.786

7.  An improved procedure for the assay of hemolysate galactose-1-phosphate uridyl transferase activity by the use of 14C-labeled galactose-1-phosphate.

Authors:  W G Ng; W R Bergren; G N Donnell
Journal:  Clin Chim Acta       Date:  1967-03       Impact factor: 3.786

8.  THE ASSAY OF GALACTOKINASE AND GALACTOSE-1-PHOSPHATE URIDYL TRANSFERASE ACTIVITY IN HUMAN ERYTHROCYTES. A PRESUMED TEST FOR HETEROZYGOUS CARRIERS OF THE GALACTOSEMIC DEFECT.

Authors:  A ROBINSON
Journal:  J Exp Med       Date:  1963-09-01       Impact factor: 14.307

9.  Diagnosis of inherited disorders of galactose metabolism.

Authors:  Carla Cuthbert; Helene Klapper; Louis Elsas
Journal:  Curr Protoc Hum Genet       Date:  2008-01

10.  Simultaneous amplification, detection, and analysis of common mutations in the galactose-1-phosphate uridyl transferase gene.

Authors:  Mohamed Jama; Lesa Nelson; Genevieve Pont-Kingdon; Rong Mao; Elaine Lyon
Journal:  J Mol Diagn       Date:  2007-09-20       Impact factor: 5.568

View more
  9 in total

1.  False-Positive Newborn Screen Using the Beutler Spot Assay for Galactosemia in Glucose-6-Phosphate Dehydrogenase Deficiency.

Authors:  Grace Stuhrman; Stefanie J Perez Juanazo; Kea Crivelly; Jennifer Smith; Hans Andersson; Eva Morava
Journal:  JIMD Rep       Date:  2017-01-12

2.  The male reproductive system in classic galactosemia: cryptorchidism and low semen volume.

Authors:  Cynthia S Gubbels; Corrine K Welt; John C M Dumoulin; Simon G F Robben; Catherine M Gordon; Gerard A J Dunselman; M Estela Rubio-Gozalbo; Gerard T Berry
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

3.  A Novel Large Deletion Encompassing the Whole of the Galactose-1-Phosphate Uridyltransferase (GALT) Gene and Extending into the Adjacent Interleukin 11 Receptor Alpha (IL11RA) Gene Causes Classic Galactosemia Associated with Additional Phenotypic Abnormalities.

Authors:  Rena Papachristoforou; Petros P Petrou; Hilary Sawyer; Maggie Williams; Anthi Drousiotou
Journal:  JIMD Rep       Date:  2013-09-04

4.  Ultra fast and sensitive liquid chromatography tandem mass spectrometry based assay for galactose-1-phosphate uridylyltransferase and galactokinase deficiencies.

Authors:  Yijun Li; Adam S Ptolemy; Lauren Harmonay; Mark Kellogg; Gerard T Berry
Journal:  Mol Genet Metab       Date:  2010-09-21       Impact factor: 4.797

5.  Biochemical changes and clinical outcomes in 34 patients with classic galactosemia.

Authors:  Tatiana Yuzyuk; Krista Viau; Ashley Andrews; Marzia Pasquali; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2018-01-19       Impact factor: 4.982

6.  SREBP-regulated adipocyte lipogenesis is dependent on substrate availability and redox modulation of mTORC1.

Authors:  Clair Crewe; Yi Zhu; Vivian A Paschoal; Nolwenn Joffin; Alexandra L Ghaben; Ruth Gordillo; Da Young Oh; Guosheng Liang; Jay D Horton; Philipp E Scherer
Journal:  JCI Insight       Date:  2019-07-16

7.  The adult galactosemic phenotype.

Authors:  Susan E Waisbren; Nancy L Potter; Catherine M Gordon; Robert C Green; Patricia Greenstein; Cynthia S Gubbels; Estela Rubio-Gozalbo; Donald Schomer; Corrine Welt; Vera Anastasoaie; Kali D'Anna; Jennifer Gentile; Chao-Yu Guo; Leah Hecht; Roberta Jackson; Bernadette M Jansma; Yijun Li; Va Lip; David T Miller; Michael Murray; Leslie Power; Nicolle Quinn; Frances Rohr; Yiping Shen; Amy Skinder-Meredith; Inge Timmers; Rachel Tunick; Ann Wessel; Bai-Lin Wu; Harvey Levy; Louis Elsas; Gerard T Berry
Journal:  J Inherit Metab Dis       Date:  2011-07-21       Impact factor: 4.982

8.  Laboratory diagnosis of galactosemia: a technical standard and guideline of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Marzia Pasquali; Chunli Yu; Bradford Coffee
Journal:  Genet Med       Date:  2017-10-26       Impact factor: 8.822

Review 9.  Galactosemia: Towards Pharmacological Chaperones.

Authors:  Samantha Banford; Thomas J McCorvie; Angel L Pey; David J Timson
Journal:  J Pers Med       Date:  2021-02-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.